Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Williams-Sonoma, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.80B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays a 1.34% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WSM | |
|---|---|---|
Market Cap | $134.06B | $26.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $251.81 |
52-Week Low | $376.62 | $168.64 |
Enterprise Value | $128.18B | $27.30B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.10 beating expectations of $2.08. Revenue trends show stabilization around $7.7-8.0B with improving net margins to 14.73%. Technical indicators show the stock testing support at $225 with RSI at oversold levels, suggesting potential near-term bounce.
The outlook remains positive with analyst consensus target of $252.23 representing 10.7% upside. Strong market share gains in home furnishings and raised full-year guidance support bullish case, though tariff pressures and competitive retail environment present ongoing risks. Institutional buying activity, including HSBC's 12.1% position increase, reinforces confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
